Matches in Wikidata for { <http://www.wikidata.org/entity/Q63577357> ?p ?o ?g. }
Showing items 1 to 76 of
76
with 100 items per page.
- Q63577357 description "clinical trial" @default.
- Q63577357 description "ensayu clínicu" @default.
- Q63577357 description "klinisch onderzoek" @default.
- Q63577357 description "клінічне випробування" @default.
- Q63577357 name "A Study of ASP2215 (Gilteritinib), Administered as Maintenance Therapy Following Induction/Consolidation Therapy for Subjects With FMS-like Tyrosine Kinase 3 (FLT3/ITD) Acute Myeloid Leukemia (AML) in First Complete Remission" @default.
- Q63577357 type Item @default.
- Q63577357 label "A Study of ASP2215 (Gilteritinib), Administered as Maintenance Therapy Following Induction/Consolidation Therapy for Subjects With FMS-like Tyrosine Kinase 3 (FLT3/ITD) Acute Myeloid Leukemia (AML) in First Complete Remission" @default.
- Q63577357 prefLabel "A Study of ASP2215 (Gilteritinib), Administered as Maintenance Therapy Following Induction/Consolidation Therapy for Subjects With FMS-like Tyrosine Kinase 3 (FLT3/ITD) Acute Myeloid Leukemia (AML) in First Complete Remission" @default.
- Q63577357 P1050 Q63577357-661F5245-6B1B-480F-B937-EFB891D80A3E @default.
- Q63577357 P1132 Q63577357-8CA32BDC-6EEB-4E80-9C79-D48F362B68FB @default.
- Q63577357 P1476 Q63577357-2A921669-10A7-4DDB-8DA0-D7A12657ECA4 @default.
- Q63577357 P17 Q63577357-157685C1-1483-4D1D-A66A-95925C741235 @default.
- Q63577357 P17 Q63577357-1BFC2CF3-DAD1-4172-91A1-FE028F8805F2 @default.
- Q63577357 P17 Q63577357-1EC4ECB1-815F-4662-AA55-B5CD705C757F @default.
- Q63577357 P17 Q63577357-2390F583-C545-4615-8457-8190E6BBEE8A @default.
- Q63577357 P17 Q63577357-2662E634-9233-4E23-B816-9E6B55D4C4EF @default.
- Q63577357 P17 Q63577357-291B59EE-DB92-453F-A885-0D9BBA0ECCC1 @default.
- Q63577357 P17 Q63577357-41FBA27F-9B3B-4125-92A1-437B393D1D6D @default.
- Q63577357 P17 Q63577357-45A45719-72EC-48C9-ADE5-5842CDD3ECCA @default.
- Q63577357 P17 Q63577357-49462750-017F-49A8-AFC8-756E0E18143B @default.
- Q63577357 P17 Q63577357-4E7547A6-FA78-41FF-9F03-6D1B91118F77 @default.
- Q63577357 P17 Q63577357-5B31141F-C2EC-46FE-87C4-EF86375F41D0 @default.
- Q63577357 P17 Q63577357-5CA5B7D5-5AF8-4A06-977C-24ABE0B58711 @default.
- Q63577357 P17 Q63577357-5D1BD41A-4F52-477F-9298-33D2E88A1D63 @default.
- Q63577357 P17 Q63577357-76547D78-8A7A-4109-92F5-F1885D233FB3 @default.
- Q63577357 P17 Q63577357-7D032414-F097-4D3E-B124-493EE10A6789 @default.
- Q63577357 P17 Q63577357-7FD3A928-72D1-4E1B-8DA9-5C03709E003C @default.
- Q63577357 P17 Q63577357-A22050D0-6BA4-449F-A499-52EF5EF05243 @default.
- Q63577357 P17 Q63577357-A72123B8-949B-4627-828D-08363D85A883 @default.
- Q63577357 P17 Q63577357-B8C8F8DB-21A8-4E40-BF85-E39BE39C6F5C @default.
- Q63577357 P17 Q63577357-BE220ED0-29FD-412B-9D9D-53B365256609 @default.
- Q63577357 P17 Q63577357-C1E3DAC4-D0EA-464A-8931-A869AD0A1F53 @default.
- Q63577357 P17 Q63577357-D031E8B4-EE6C-45F3-9FC3-C3DD262C22B7 @default.
- Q63577357 P17 Q63577357-EFCB5D60-9C11-4BDF-B9F4-AAE136848DEC @default.
- Q63577357 P17 Q63577357-F3D41852-0EEA-4C7A-8290-BD1805D50F6F @default.
- Q63577357 P2899 Q63577357-891CDE2A-3882-4D66-B7C1-978AF0461611 @default.
- Q63577357 P3098 Q63577357-F5D288EA-D676-4EEC-9ABD-2361B42F9001 @default.
- Q63577357 P31 Q63577357-158111C3-CD59-4896-807D-A453F9C801A0 @default.
- Q63577357 P580 Q63577357-DEC1A1A9-C09E-48F0-AF16-C0D2D772CFA0 @default.
- Q63577357 P582 Q63577357-8DF27D88-3140-44C4-A35C-F0011E9E0E8D @default.
- Q63577357 P6099 Q63577357-45EE3BAD-BFA4-4F7A-9E9E-1E7AA8348882 @default.
- Q63577357 P8363 Q63577357-C0372357-386B-4A58-8AAF-0FAA30210659 @default.
- Q63577357 P1050 Q29496 @default.
- Q63577357 P1132 "+354" @default.
- Q63577357 P1476 "A Phase 3 Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial of the FLT3 Inhibitor Gilteritinib (ASP2215) Administered as Maintenance Therapy Following Induction/Consolidation Therapy for Subjects With FLT3/ITD AML in First Complete Remission" @default.
- Q63577357 P17 Q142 @default.
- Q63577357 P17 Q145 @default.
- Q63577357 P17 Q155 @default.
- Q63577357 P17 Q16 @default.
- Q63577357 P17 Q17 @default.
- Q63577357 P17 Q183 @default.
- Q63577357 P17 Q218 @default.
- Q63577357 P17 Q224 @default.
- Q63577357 P17 Q28 @default.
- Q63577357 P17 Q29 @default.
- Q63577357 P17 Q298 @default.
- Q63577357 P17 Q30 @default.
- Q63577357 P17 Q34 @default.
- Q63577357 P17 Q35 @default.
- Q63577357 P17 Q36 @default.
- Q63577357 P17 Q38 @default.
- Q63577357 P17 Q403 @default.
- Q63577357 P17 Q408 @default.
- Q63577357 P17 Q41 @default.
- Q63577357 P17 Q414 @default.
- Q63577357 P17 Q43 @default.
- Q63577357 P17 Q45 @default.
- Q63577357 P17 Q801 @default.
- Q63577357 P17 Q865 @default.
- Q63577357 P2899 "+18" @default.
- Q63577357 P3098 "NCT02927262" @default.
- Q63577357 P31 Q30612 @default.
- Q63577357 P580 "2017-01-10T00:00:00Z" @default.
- Q63577357 P582 "2024-03-01T00:00:00Z" @default.
- Q63577357 P6099 Q42824827 @default.
- Q63577357 P8363 Q78089383 @default.